Biosimilars for Retina and Inflammatory Disease Get EMA Nod

The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, efficacy, and cost-effectiveness compared with reference drugs.
Medscape News Europe